person · Reporting owner

MCKEON BRIAN P

Disclosed activity across 4 companies

Tapewire entity: 38418
SEC CIK: 0001219445

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	May 20, 2026	May 23, 2026
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	June 12, 2026	June 15, 2026
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	EVP, CFO and Treasurer	February 14, 2025	February 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 20, 2026 · Filed May 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	38,536	Ending reported balance After 2026-05-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 40,011 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 38,536
Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20	Direct	11,538	Reported balance After 2026-05-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	5,409	Reported balance After 2026-05-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F4: This award is fully vested in accordance with its terms.
Ordinary SharesSEC Table I · non-derivative	IndirectBy the Brian P. McKeon Trust	10,000	Reported balance Holding disclosure · report date 2026-05-20 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 10,000 F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.

F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F4: This award is fully vested in accordance with its terms.

DENTSPLY SIRONA Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy a Trust	10,000	Reported balance After 2026-06-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-12 · Purchase · Acquired 10,000 · Balance 10,000
Common StockSEC Table I · non-derivative	Direct	28,887	Reported balance Holding disclosure · report date 2026-06-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 28,887

IDEXX LABORATORIES INC /DE

Report date February 14, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,208.5926	Reported balance After 2025-02-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-02-14 · Exercise / conversion · Acquired 252 · Balance 31,208.5926 F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.
Common StockSEC Table I · non-derivative	Direct	31,511.5926	Reported balance After 2025-02-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-02-14 · Exercise / conversion · Acquired 303 · Balance 31,511.5926
Common StockSEC Table I · non-derivative	Direct	31,819.5926	Reported balance After 2025-02-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2025-02-14 · Exercise / conversion · Acquired 308 · Balance 31,819.5926
Common StockSEC Table I · non-derivative	Direct	32,118.5926	Reported balance After 2025-02-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2025-02-14 · Exercise / conversion · Acquired 299 · Balance 32,118.5926
Common StockSEC Table I · non-derivative	Direct	31,549.5926	Reported balance After 2025-02-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2025-02-14 · Tax withholding · Disposed 569 · Balance 31,549.5926
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-02-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-02-14 · Exercise / conversion · Disposed 252 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	303	Reported balance After 2025-02-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-02-14 · Exercise / conversion · Disposed 303 · Balance 303 F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	615	Reported balance After 2025-02-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-02-14 · Exercise / conversion · Disposed 308 · Balance 615 F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	894	Reported balance After 2025-02-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-02-14 · Exercise / conversion · Disposed 299 · Balance 894 F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.
Common StockSEC Table I · non-derivative	Indirectby Estony McKeon Family, LLC	18,050	Reported balance Holding disclosure · report date 2025-02-14 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 18,050

Filing footnotes · ownership attribution and instrument terms

F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.

F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.

F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.

F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.

F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ATHENAHEALTH INC

Report date February 11, 2019 · Filed February 13, 2019

Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-02-11 transaction · row 1 1 source row Row 1 · 2019-02-11 · Disposition to issuer · Disposed 2,721 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes. F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes.

F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 16, 2022 Filed Feb 17, 2022 22:49 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	706	Not disclosed Strike: $141.60	Not disclosed	Disclosure SEC source: 0001567619-22-004967 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 706 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 706 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on February 14, 2022. Read SEC document
February 16, 2022 Filed Feb 17, 2022 22:49 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	706	$141.60	$99,969.60	Disclosure SEC source: 0001567619-22-004967 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,153.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	253	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,785 Underlying: Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F10 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	433	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,038 Underlying: Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F10 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	435	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 13 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,471 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F10 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	505	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,906 Underlying: Common Stock · 505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F10 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	459	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,411 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F10 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	1,212	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,870 Underlying: Common Stock · 1,212 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F10 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantIncentive Stock Option (right-to-buy) · Derivative	197	Not disclosed Strike: $505.53	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F10 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	10,502	Not disclosed Strike: $505.53	Not disclosed	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,502 Underlying: Common Stock · 10,502 shares Expires 2032-02-13 F10 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	964	$505.53	$487,330.92	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,447.6426 Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	253	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,411.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	433	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,158.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	435	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,725.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	505	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,290.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2022 Filed Feb 17, 2022 00:25 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	459	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004784 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,785.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2021. Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	4,446	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-004564 · form4.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,890 Underlying: Ordinary Shares · 4,446 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,223	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-004564 · form4.xml · derivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This restricted stock unit award vested in full on 2/10/2022. F3 · derivative.expiration_date: This restricted stock unit award vested in full on 2/10/2022. Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,823	$23.55	$42,931.65	Disclosure SEC source: 0001127602-22-004564 · form4.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,934 Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	4,446	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-004564 · form4.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	912	$23.55	$21,477.60	Disclosure SEC source: 0001127602-22-004564 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,311 Read SEC document
February 10, 2022 Filed Feb 11, 2022 21:32 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,223	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-004564 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
November 12, 2021 Filed Nov 15, 2021 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	9,225	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-21-020493 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,225 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document
November 12, 2021 Filed Nov 15, 2021 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,273	$621.26	$1,412,126.03	Disclosure SEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $621.045 to $621.815. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 12, 2021 Filed Nov 15, 2021 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	6,952	$620.55	$4,314,062.21	Disclosure SEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,589.6426 F1 · price: This transaction was executed in multiple trades at prices ranging from $620.00 to $621.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 12, 2021 Filed Nov 15, 2021 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	9,225	$67.85	$625,916.25	Disclosure SEC source: 0001567619-21-020493 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,541.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	20,000	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,225 Underlying: Common Stock · 20,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · price: Not applicable. F10 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	872	$629.80	$549,185.95	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F9 · price: This transaction was executed in multiple trades at prices ranging from $629.46 to $630.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,375	$628.78	$864,574.15	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,188.6426 F8 · price: This transaction was executed in multiple trades at prices ranging from $628.34.10 to $629.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,974	$627.97	$1,867,572.07	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,563.6426 F7 · price: This transaction was executed in multiple trades at prices ranging from $627.32 to $628.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,813	$626.74	$1,136,281.61	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,537.6426 F6 · price: This transaction was executed in multiple trades at prices ranging from $626.10 to $627.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,326	$625.46	$1,454,830.89	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,350.6426 F5 · price: This transaction was executed in multiple trades at prices ranging from $625.06 to $626.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,142	$624.53	$1,337,747.12	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,676.6426 F4 · price: This transaction was executed in multiple trades at prices ranging from $624.04 to $625.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,493	$623.34	$930,649.01	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,818.6426 F3 · price: This transaction was executed in multiple trades at prices ranging from $622.97 to $623.965. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	5,743	$622.36	$3,574,234.73	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,311.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $621.79 to $622.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,262	$621.40	$784,203.01	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,054.6426 F1 · price: This transaction was executed in multiple trades at prices ranging from $620.78 to $621.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:29 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	20,000	$67.85	$1,357,000.00	Disclosure SEC source: 0001567619-21-020098 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,316.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 09, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	6,310	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · derivative · entry 15 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,225 Underlying: Common Stock · 6,310 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Not applicable. F12 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document
November 09, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	607	$631.01	$383,023.56	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F11 · price: This transaction was executed in multiple trades at prices ranging from $631.005 to $631.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 09, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	5,703	$630.13	$3,593,652.49	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,923.6426 F10 · price: This transaction was executed in multiple trades at prices ranging from $630.00 to $631.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 09, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	6,310	$67.85	$428,133.50	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,626.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	10,000	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · derivative · entry 14 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,535 Underlying: Common Stock · 10,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Not applicable. F12 · derivative.exercise_date: Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	110	$632.19	$69,541.14	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,316.6426 F9 · price: This transaction was executed in multiple trades at prices ranging from $632.01 to $632.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	743	$631.39	$469,121.66	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,426.6426 F8 · price: This transaction was executed in multiple trades at prices ranging from $631.10 to $631.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	971	$630.39	$612,112.28	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,169.6426 F7 · price: This transaction was executed in multiple trades at prices ranging from $630.03 to $630.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,094	$629.63	$1,318,446.27	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,140.6426 F6 · price: This transaction was executed in multiple trades at prices ranging from $629.10 to $629.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,356	$628.19	$1,480,023.89	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,234.6426 F5 · price: This transaction was executed in multiple trades at prices ranging from $628.01 to $628.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,326	$627.41	$831,941.55	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,590.6426 F4 · price: This transaction was executed in multiple trades at prices ranging from $627.07 to $628.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,100	$626.47	$689,122.17	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,916.6426 F3 · price: This transaction was executed in multiple trades at prices ranging from $626.10 to $627.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,300	$625.25	$812,824.09	Disclosure SEC source: 0001567619-21-019740 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,016.6426 F2 · price: This transaction was executed in multiple trades at prices ranging from $625.00 to $625.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.